1 Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE and Forastiere AA: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21(1): 92-98, 2003. PMID: 12506176. DOI: 10.1200/JCO.2003.01.008
2 Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J and Cooper J: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22): 2091-2098, 2003. PMID: 14645636. DOI: 10.1056/NEJMoa031317
3 Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK and Radiation Therapy Oncology Group 9501/Intergroup: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous- cell carcinoma of the head and neck. N Engl J Med 350(19): 1937- 1944, 2004. PMID: 15128893. DOI: 10.1056/NEJMoa032646
4 Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M and European Organization for Research and Treatment of Cancer Trial 22931: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19): 1945-1952, 2004. PMID: 15128894. DOI: 10.1056/NEJMoa032641
5 Matsuura K, Sagai S, Katagiri K, Imai T, Ishida E, Shiga K and Saijo S: Efficacy and safety of chemoradiotherapy when performed by head and neck surgeons. Head Neck Cancer 37(4): 454-459, 2011. DOI: 10.5981/jjhnc.37.454
6 Ogawa T: Chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. Otologia Fukuoka 61(S1): S9- 14, 2015.
7 Nakano K, Sato Y, Toshiyasu T, Sato Y, Inagaki L, Tomomatsu J, Sasaki T, Shimbashi W, Fukushima H, Yonekawa H, Mitani H, Kawabata K and Takahashi S: Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapy. Mol Clin Oncol 4(2): 303-309, 2016. PMID: 26893880. DOI: 10.3892/mco.2015.687
8 Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, Castro A, Licitra L, Adelstein D and Vermorken JB: Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist 22(9): 1056-1066, 2017. PMID: 28533474. DOI: 10.1634/theoncologist.2017-0015
9 Matsuyama H, Yamazaki K, Okabe R, Ueki Y, Shodo R, Omata J, Sato Y, Ota H, Takahashi T, Tomita M, Yokoyama Y, Togashi T, Aoyama H, Abe E, Saijo Y, Katsura K, Soga M, Sugita T, Matsumoto Y, Tsuchida E and Horii A: Multicenter phase I/II study of chemoradiotherapy with high-dose CDDP for head and neck squamous cell carcinoma in Japan. Auris Nasus Larynx 45(5): 1086-1092, 2018. PMID: 29567334. DOI: 10.1016/ j.anl.2018.02.008
10 Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, Mitani H, Iwae S, Fujimoto Y, Onozawa Y, Hanai N, Ogawa T, Hara H, Monden N, Shimura E, Minami S, Fujii T, Tanaka K, Homma A, Yoshimoto S, Oridate N, Omori K, Ueda T, Okami K, Ota I, Shiga K, Sugasawa M, Asakage T, Saito Y, Murono S, Nishimura Y, Nakamura K, Hayashi R and Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG): Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial. J Clin Oncol 40(18): 1980-1990, 2022. PMID: 35230884. DOI: 10.1200/JCO.21.01293
11 Faig J, Haughton M, Taylor RC, D’Agostino RB Jr, Whelen MJ, Porosnicu Rodriguez KA, Bonomi M, Murea M and Porosnicu M: Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol 41(5): 432-440, 2018. PMID: 27281266. DOI: 10.1097/COC.0000000000000301
12 Patimarattananan T, Nongnuch A, Pattaranutaporn P, Unwanatham N, Jiarpinitnun C and Ngamphaiboon N: Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin. Support Care Cancer 29(2): 877-887, 2021. PMID: 32524284. DOI: 10.1007/s00520-020-05566-y
13 Motohashi H and Inui K: Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J 15(2): 581-588, 2013. PMID: 23435786. DOI: 10.1208/s12248-013-9465-7
14 de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ, Planting AS, Graveland WJ, Stoter G and Verweij J: Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88(8): 1199-1206, 2003. PMID: 12698184. DOI: 10.1038/sj.bjc.6600884
15 Mizuno T, Ishikawa K, Sato W, Koike T, Kushida M, Miyagawa Y, Yamada K, Hirata S, Imai E and Noda Y: The risk factors of severe acute kidney injury induced by cisplatin. Oncology 85(6): 364-369, 2013. PMID: 24335484. DOI: 10.1159/000356587
16 Kumagai M, Akamine Y, Ambai A, Wada Y, Tozawa T, Sasajima M, Kumagai S, Hashimoto G and Miura M: The effects of antihypertensive drugs on renal function in patients with esophageal cancer treated with cisplatin. JSHP 55(7): 805-812, 2019.
17 Kimura T, Ozawa T, Hanai N, Hirakawa H, Suzuki H, Hosoi H and Hasegawa Y: Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer. J Otolaryngol Head Neck Surg 47(1): 10, 2018. PMID: 29394952. DOI: 10.1186/s40463-018-0261-3
18 Ikemura K, Oshima K, Enokiya T, Okamoto A, Oda H, Mizuno T, Ishinaga H, Muraki Y, Iwamoto T, Takeuchi K, Katayama N and Okuda M: Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study. Cancer Chemother Pharmacol 79(5): 943-949, 2017. PMID: 28364288. DOI: 10.1007/s00280-017-3296-7
19 Galfetti E, Cerutti A, Ghielmini M, Zucca E and Wannesson L: Risk factors for renal toxicity after inpatient cisplatin administration. BMC Pharmacol Toxicol 21(1): 19, 2020. PMID: 32122396. DOI: 10.1186/s40360-020-0398-3
20 Okamoto K, Saito Y, Narumi K, Furugen A, Iseki K and Kobayashi M: Non-steroidal anti-inflammatory drugs are a risk factor for cisplatin-induced nephrotoxicity: a meta-analysis of retrospective studies. Anticancer Res 40(3): 1747-1751, 2020. PMID: 32132083. DOI: 10.21873/anticanres.14128
21 Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P and Acute Dialysis Quality Initiative workgroup: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8(4): R204-R212, 2004. PMID: 15312219. DOI: 10.1186/cc2872
22 Yamamoto Y, Watanabe K, Tsukiyama I, Matsushita H, Yabushita H, Matsuura K and Wakatsuki A: Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin. Anticancer Res 35(4): 2199-2204, 2015. PMID: 25862878.
23 Yamamoto Y, Watanabe K, Tsukiyama I, Yabushita H, Matsuura K and Wakatsuki A: Hydration with 15 mEq magnesium is effective at reducingthe risk for cisplatin-induced nephrotoxicity in patients receiving cisplatin (≥50 mg/m2) combination chemotherapy. Anticancer Res 36(4): 1873-1877, 2016. PMID: 27069173.
24 Vittinghoff E and McCulloch CE: Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165(6): 710-718, 2007. PMID: 17182981. DOI: 10.1093/aje/kwk052
25 Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3): 452- 458, 2013. PMID: 23208313. DOI: 10.1038/bmt.2012.244
26 Ang KK: Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol 22(23): 4657-4659, 2004. PMID: 15534361. DOI: 10.1200/JCO.2004.07.962
27 Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M Jr, Bossi P, Worden FP, Langendijk JA, Eisbruch A, Mendenhall WM, Lee AW, Harrison LB, Bradford CR, Smee R, Silver CE, Rinaldo A and Ferlito A: Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head Neck 38 Suppl 1: E2151-E2158, 2016. PMID: 25735803. DOI: 10.1002/hed.24026
28 Inose R, Takahashi K, Yoshimura N, Kawaguchi T, Takada M and Nagayama K: The factors reducing relative dose intensity of cisplatin and vinorelbine as adjuvant chemotherapy in patients with non-small cell lung cancer. Oncomedicine 3: 9-14, 2018.
29 Uozumi J, Ueda T, Yasumasu T, Koikawa Y and Kumazawa J: Calcium blockers enhance cisplatin-induced nephrotoxicity in rats. Int Urol Nephrol 24(5): 549-553, 1992. PMID: 1459833. DOI: 10.1007/BF02550124
30 Deray G, Dubois M, Beaufils H, Cacoub P, Anouar M, Jaudon MC, Baumelou A, Jouanneau C and Jacobs C: Effects of nifedipine on cisplatinum-induced nephrotoxicity in rats. Clin Nephrol 30(3): 146-150, 1988. PMID: 3180522.
31 Hosoda A, Matsumoto Y, Toriyama Y, Tsuji T, Yoshida Y, Masamichi S and Kohno T: Telmisartan exacerbates cisplatin- induced nephrotoxicity in a mouse model. Biol Pharm Bull 43(9): 1331-1337, 2020. PMID: 32879207. DOI: 10.1248/bpb.b20-00174
32 Hayashi K, Nagahama T, Oka K, Epstein M and Saruta T: Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 19(1): 31-36, 1996. PMID: 8829821. DOI: 10.1291/hypres.19.31
33 Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M and Schwab M: Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One 6(7): e22163, 2011. PMID: 21779389. DOI: 10.1371/journal.pone.0022163
34 Gao H, Zhang S, Hu T, Qu X, Zhai J, Zhang Y, Tao L, Yin J and Song Y: Omeprazole protects against cisplatin-induced nephrotoxicity by alleviating oxidative stress, inflammation, and transporter-mediated cisplatin accumulation in rats and HK- 2 cells. Chem Biol Interact 297: 130-140, 2019. PMID: 30452898. DOI: 10.1016/j.cbi.2018.11.008
35 Ismail RS, El-Awady MS and Hassan MH: Pantoprazole abrogated cisplatin-induced nephrotoxicity in mice via suppression of inflammation, apoptosis, and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol 393(7): 1161-1171, 2020. PMID: 31950223. DOI: 10.1007/s00210-020-01823-3
36 Gao H, Wang X, Qu X, Zhai J, Tao L, Zhang Y, Song Y and Zhang W: Omeprazole attenuates cisplatin-induced kidney injury through suppression of the TLR4/NF-κB/NLRP3 signaling pathway. Toxicology 440: 152487, 2020. PMID: 32418911. DOI: 10.1016/j.tox.2020.152487
37 Hiramatsu SI, Ikemura K, Fujisawa Y, Iwamoto T and Okuda M: Concomitant lansoprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats. Biopharm Drug Dispos 41(6): 239-247, 2020. PMID: 32473602. DOI: 10.1002/bdd.2242
38 Ghonaim E, El-Haggar S and Gohar S: Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial. Med Oncol 38(9): 108, 2021. PMID: 34357466. DOI: 10.1007/s12032-021-01558-y
39 Wijarnpreecha K, Thongprayoon C, Chesdachai S, Panjawatanana P, Ungprasert P and Cheungpasitporn W: Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis. Dig Dis Sci 62(10): 2821-2827, 2017. PMID: 28836158. DOI: 10.1007/s10620-017-4725-5
40 Nochaiwong S, Ruengorn C, Awiphan R, Koyratkoson K, Chaisai C, Noppakun K, Chongruksut W and Thavorn K: The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta- analysis. Nephrol Dial Transplant 33(2): 331-342, 2018. PMID: 28339835. DOI: 10.1093/ndt/gfw470
41 Săftescu S, Popovici D, Oprean C, Negru A, Haiduc A, Stanca S, Malița DC, Volovăț S and Negru Ș: Determining factors of renal dysfunction during cisplatin chemotherapy. Exp Ther Med 21(1): 83, 2021. PMID: 33363594. DOI: 10.3892/etm.2020.9516
42 Knight K, Wade S and Balducci L: Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116(Suppl 7A): 11S-26S, 2004. PMID: 15050883. DOI: 10.1016/j.amjmed.2003.12.008
43 Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 17(1): 17-25, 2006. PMID: 16291837. DOI: 10.1681/ ASN.2005070757
44 Kong D, Zhuo L, Gao C, Shi S, Wang N, Huang Z, Li W and Hao L: Erythropoietin protects against cisplatin-induced nephrotoxicity by attenuating endoplasmic reticulum stress- induced apoptosis. J Nephrol 26(1): 219-227, 2013. PMID: 22711436. DOI: 10.5301/jn.5000177
45 Yang Y, Yu X, Zhang Y, Ding G, Zhu C, Huang S, Jia Z and Zhang A: Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury. Clin Sci (Lond) 132(7): 825-838, 2018. PMID: 29581249. DOI: 10.1042/CS20171625
論文の公開元へ
